These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37972431)

  • 1. Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure.
    Lee L; Kim H
    Value Health Reg Issues; 2024 Mar; 40():27-34. PubMed ID: 37972431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
    Clarke PM; Fitzgerald EM
    Med J Aust; 2010 Jun; 192(11):633-6. PubMed ID: 20528715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
    Bae G; Park C; Lee H; Han E; Kim DS; Jang S
    BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
    Thai LP; Moss JR; Godman B; Vitry AI
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
    Simoens S; Sinnaeve PR
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
    Minard LV; Corkum A; Sketris I; Fisher J; Zhang Y; Saleh A
    PLoS One; 2016; 11(7):e0158608. PubMed ID: 27434392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does price regulation affect atorvastatin sales in India? An impact assessment through interrupted time series analysis.
    Selvaraj S; Farooqui HH; Mehta A
    BMJ Open; 2019 Jan; 9(1):e024200. PubMed ID: 30679294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
    Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
    JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target.
    Lum CJ; Nakagawa K; Shohet RV; Seto TB; Taira DA
    Hawaii J Med Public Health; 2017 Apr; 76(4):99-102. PubMed ID: 28428922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database.
    Hsieh HC; Hsu JC; Lu CY
    BMJ Open; 2017 May; 7(5):e014150. PubMed ID: 28515189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006.
    Li P; Schwartz JS; Doshi JA
    J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27836822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
    Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
    Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.
    Salami JA; Warraich H; Valero-Elizondo J; Spatz ES; Desai NR; Rana JS; Virani SS; Blankstein R; Khera A; Blaha MJ; Blumenthal RS; Lloyd-Jones D; Nasir K
    JAMA Cardiol; 2017 Jan; 2(1):56-65. PubMed ID: 27842171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has cost inhibited the uptake of more potent statins in England?
    Chapman SR; Fitzpatrick RW; Aladul MI
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):984-991. PubMed ID: 28612964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
    Yu JM; Chen WM; Shia BC; Wu SY
    Eur J Clin Pharmacol; 2023 May; 79(5):687-700. PubMed ID: 37010535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013.
    Fuksa L; Vocelka M; Vytrisalova M
    Health Policy; 2015 Sep; 119(9):1255-64. PubMed ID: 25929214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.